Cornercap Investment Counsel Inc. Has $1.40 Million Holdings in Hologic, Inc. (NASDAQ:HOLX)

Cornercap Investment Counsel Inc. trimmed its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 34.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,190 shares of the medical equipment provider's stock after selling 9,126 shares during the period. Cornercap Investment Counsel Inc.'s holdings in Hologic were worth $1,400,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Innealta Capital LLC bought a new stake in Hologic in the 2nd quarter valued at $25,000. Wolff Wiese Magana LLC purchased a new position in Hologic in the 3rd quarter worth about $25,000. iA Global Asset Management Inc. purchased a new stake in shares of Hologic during the 1st quarter worth $37,000. Sunbelt Securities Inc. purchased a new position in Hologic in the second quarter worth $37,000. Finally, Cromwell Holdings LLC grew its stake in shares of Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider's stock worth $44,000 after acquiring an additional 416 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Price Performance

Shares of HOLX traded up $1.06 on Friday, reaching $78.60. The stock had a trading volume of 1,819,241 shares, compared to its average volume of 1,593,877. The firm has a 50-day moving average of $80.77 and a 200 day moving average of $78.22. The firm has a market capitalization of $18.26 billion, a PE ratio of 23.29, a PEG ratio of 2.50 and a beta of 0.98. Hologic, Inc. has a twelve month low of $67.59 and a twelve month high of $84.67. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. During the same quarter in the previous year, the company posted $0.89 EPS. The business's revenue was up 4.5% on a year-over-year basis. Sell-side analysts expect that Hologic, Inc. will post 4.27 EPS for the current year.

Analysts Set New Price Targets

HOLX has been the subject of a number of research reports. UBS Group lifted their target price on Hologic from $84.00 to $90.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. Evercore ISI upped their price objective on shares of Hologic from $78.00 to $82.00 and gave the stock an "in-line" rating in a research report on Tuesday, October 1st. Needham & Company LLC reiterated a "buy" rating and issued a $90.00 price objective on shares of Hologic in a report on Tuesday, October 15th. Royal Bank of Canada raised their price target on shares of Hologic from $86.00 to $89.00 and gave the stock a "sector perform" rating in a research note on Tuesday, November 5th. Finally, Leerink Partners lowered their price objective on Hologic from $95.00 to $90.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 8th. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $89.91.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.